Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Pharmacorp Rx closes $23-million bought deal offering

By The Northwire Desk — AI Analysis Nov 12, 2025 · 20:07 PCRX · 0.44 Pharmacorp Rx Inc
PCRX · Price

Executive Summary

  • Pharmacorp Rx Inc. has closed a C$23 million bought deal public offering, raising aggregate gross proceeds of approximately $23.0 million through the sale of 54,855,000 units.
  • The offering was co-led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Ltd., with Raymond James Ltd., iA Private Wealth Inc., and Bloom Burton Securities Inc. participating as underwriters.
  • Net proceeds are designated for future acquisition opportunities and general working capital requirements, with no change of control or new insiders created.

Key Details

  • Gross Proceeds: Approximately $23.0 million.
  • Units Sold: 54,855,000 units.
  • Price Per Unit: 42 cents CAD.
  • Underwriters: Co-led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Ltd.; included Raymond James Ltd., iA Private Wealth Inc., and Bloom Burton Securities Inc.
  • Overallotment: The gross proceeds include the full exercise of the overallotment option.
  • Unit Composition: Each unit consists of one common share and one-half of one common share purchase warrant.
  • Warrant Terms:
    • Each whole warrant entitles the holder to acquire one common share.
    • Exercise Price: 50 cents per common share.
    • Expiration Date: November 12, 2027.
    • Listing: Conditional approval received for TSX Venture Exchange under symbol PCRX.WT; subject to final acceptance.
  • Use of Proceeds: Future acquisition opportunities and general working capital requirements.
  • Related Party Transactions:
    • Directors and officers purchased an aggregate of 3,762,010 units.
    • Exemptions from related party policies were utilized under MI 61-101 Sections 5.5(b) and 5.7(a).
    • No new insiders were created, and no change of control occurred.
  • Underwriter Compensation:
    • Cash Commission: 6.0% of gross proceeds (3.0% for president's list purchasers; 0% for certain insiders), totaling $1,134,633.
    • Broker Warrants: 2,026,130 broker warrants issued.
    • Broker Warrant Terms: Exercisable up to November 12, 2026, to acquire one unit at an exercise price of 42 cents per unit.
  • Regulatory Filings: Offered via prospectus supplement dated November 7, 2025, to the short form base shelf prospectus dated October 14, 2025.

Notable Quotes

  • None provided in the text.
Read the original news release →

More from Pharmacorp Rx Inc

Jun 29, 2026 · 07:16

PharmaCorp Announces Definitive Agreement to Acquire Western Canada PharmaChoice Bannered Pharmacy

M&A / Property Jun 01, 2026 · 09:00

PharmaCorp Rx Inc. Consolidates Eastern Canada Footprint as Q1 Revenue Surges 79%, Yet Margin Compression and Integration Pace Demand Caution

Earnings May 25, 2026 · 09:27

PharmaCorp Rx Advances National Footprint with Definitive Acquisition, Pipeline Execution Validates Growth Strategy

M&A / Property May 01, 2026 · 17:00

PharmaCorp Rx Inc.

M&A / Property Apr 30, 2026 · 11:04

PharmaCorp Doubles Footprint, Cash Reserves Depleted by Aggressive Buyout

M&A / Property Apr 29, 2026 · 20:51

PharmaCorp Rx Confirms M&A Execution but Stock Stalls Near Dilutive Offering Price

Earnings